CDKN2A and melanoma: p16 expression appears typically strong in benign nevi, reduced in dysplastic nevi and RGP melanomas, and lost (as nuclear p16) in VGP melanomas (Gray-Schopfer et al., 2006; Keller-Melchior et al., 1998; Talve et al., 1997).